Growth factors (GFs) are indispensable for therapeutic and industrial applications, from cultivated meat production to pharmaceuticals. However, their inherent instability—short half-lives and low yields—results in significant loss during production and high costs, limiting accessibility. This is especially true for hepatocyte growth factor (HGF), a promising agent in hair regeneration treatments demonstrated in preclinical studies (e.g. PMC5101615), and other numerous patented GFs for anti-wrinkle cosmetics (doi:10.3389/fbioe.2025.1527854). Traditional production systems present critical challenges, including contamination risks, high costs, and low scalability. Furthermore, stem-cell-based treatments relying on GFs are prohibitively expensive and ethically constrained, especially for large consumer markets. acib offers a sustainable alternative: a yeast-based purification-free molecular farming platform combined with advanced protein engineering techniques to develop highly stable and cost-effective GFs for hair and skin regeneration.